within Pharmacolibrary.Drugs.ATC.N;

model N04BA01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.3,
    Cl             = 0.013333333333333334,
    adminDuration  = 600,
    adminMass      = 0.25,
    adminCount     = 1,
    Vd             = 0.0016,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 900
  );

  annotation(Documentation(
    info ="<html><body><p>Levodopa is a precursor of dopamine used primarily in the treatment of Parkinson's disease and parkinsonism. It is usually administered with carbidopa or benserazide to inhibit peripheral metabolism, allowing more levodopa to reach the brain. Levodopa remains an approved drug today and is a mainstay treatment for motor symptoms of Parkinson's disease.</p><h4>Pharmacokinetics</h4><p>Typical adult patients with Parkinson's disease, both sexes, ages 40-80 years. Pharmacokinetic parameters derived from oral administration studies.</p><h4>References</h4><ol><li><p>Leta, V, et al., &amp; Ray Chaudhuri, K (2023). Gastrointestinal barriers to levodopa transport and absorption in Parkinson&#x27;s disease. <i>European journal of neurology</i> 30(5) 1465–1480. DOI:<a href=&quot;https://doi.org/10.1111/ene.15734&quot;>10.1111/ene.15734</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36757008/&quot;>https://pubmed.ncbi.nlm.nih.gov/36757008</a></p></li><li><p>Othman, AA, et al., &amp; Dutta, S (2017). Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa. <i>Journal of Parkinson&#x27;s disease</i> 7(2) 275–278. DOI:<a href=&quot;https://doi.org/10.3233/JPD-161042&quot;>10.3233/JPD-161042</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28211816/&quot;>https://pubmed.ncbi.nlm.nih.gov/28211816</a></p></li><li><p>Safirstein, BE, et al., &amp; Oh, C (2020). Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson&#x27;s Disease. <i>Clinical therapeutics</i> 42(6) 1034–1046. DOI:<a href=&quot;https://doi.org/10.1016/j.clinthera.2020.04.004&quot;>10.1016/j.clinthera.2020.04.004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32482490/&quot;>https://pubmed.ncbi.nlm.nih.gov/32482490</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N04BA01;
